Evidence map›Paper›PMID 18973733›Full record

ReviewCurrent pain and headache reports2008

The treatment of psoriatic arthritis and inflammatory spondylitis.

Hernan Castro-Rueda, Arthur Kavanaugh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hernan Castro-RuedaCenter for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA 92093-0943, USA.
Arthur Kavanaugh
University of California System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NSAIDs still remain the initial therapeutic modality for psoriatic arthritis and inflammatory spondylitis. Disease-modifying antirheumatic drugs have only been proven to be useful in peripheral arthritis, without efficacy in axial inflammatory spondylitis. In recent years, the introduction of tumor necrosis alpha inhibitors into clinical practice has produced a substantial impact in both peripheral and axial disease, with improvement in pain, function, and quality of life. Factors such as cost-effectiveness and safety will need to be better characterized over time.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticHumansInflammation MediatorsSpondylitisTreatment OutcomeTumor Necrosis Factor-alphaAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsInflammation MediatorsTumor Necrosis Factor-alpha

Identifiers

PMID18973733
OpenAlexW2085075863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.